XPR – Lifestyle Demo
Author:
Prelude Therapeutics, Incorporated
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
March 17, 2026
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
March 10, 2026